Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 53Leukemia, Myeloid, Acute 52Neoplasm Metastasis 45Carcinoma, Non-Small-Cell Lung 40Prostatic Neoplasms 37Breast Neoplasms 36Multiple Myeloma 31Colorectal Neoplasms 29Pancreatic Neoplasms 26Carcinoma, Renal Cell 25Melanoma 23Ovarian Neoplasms 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 20Lymphoma 20Leukemia, Lymphocytic, Chronic, B-Cell 20Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Urinary Bladder Neoplasms 16Carcinoma, Hepatocellular 16Squamous Cell Carcinoma of Head and Neck 15Glioblastoma 15Fallopian Tube Neoplasms 14Oropharyngeal Neoplasms 13Glioma 13Endometrial Neoplasms 13Sarcoma 12Mouth Neoplasms 12Lymphoma, Non-Hodgkin 12

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Specimen Handling × 90 days × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡